[Form 4] Castle Biosciences, Inc. Insider Trading Activity
Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), reported the sale of 12,677 shares of the company's common stock in a transaction executed at a weighted-average price of $22.019 per share. The reported sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and, after the transaction, the reporting person beneficially owned 141,116 shares. The filing discloses that the sale occurred in multiple trades at prices ranging from $22.000 to $22.145 and that the reporting person will provide detailed trade-level information on request.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences (CSTL), ha venduto 12.677 azioni dell'ordinario della società in un'operazione eseguita a un prezzo medio ponderato di 22,019 $ per azione. La vendita è stata effettuata ai sensi di un piano di negoziazione ai sensi della Rule 10b5-1 adottato dalla persona che ha presentato la segnalazione e, dopo la transazione, la stessa deteneva beneficiariamente 141.116 azioni. La comunicazione specifica che la vendita è avvenuta in più operazioni a prezzi compresi tra 22,000 $ e 22,145 $ e che la persona che ha presentato la segnalazione fornirà informazioni dettagliate a livello di singole operazioni su richiesta.
Kristen M. Oelschlager, directora de operaciones de Castle Biosciences (CSTL), vendió 12.677 acciones del capital social de la compañía en una transacción ejecutada a un precio medio ponderado de 22,019 $ por acción. La venta se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado por la persona informante y, tras la transacción, dicha persona poseía de forma beneficiaria 141.116 acciones. La presentación revela que la venta se efectuó en múltiples operaciones a precios que oscilaron entre 22,000 $ y 22,145 $ y que la persona informante facilitará información detallada por operación si se le solicita.
Castle Biosciences(CSTL)의 최고운영책임자(Chief Operating Officer)인 Kristen M. Oelschlager는 회사 보통주 12,677주를 주당 가중평균 가격 22.019달러에 매도했습니다. 해당 매도는 보고인이 채택한 Rule 10b5-1 거래계획에 따라 이루어졌으며, 거래 후 보고인은 실질적으로 141,116주를 보유하고 있습니다. 제출서류는 매도가 여러 건의 거래로 이루어졌으며 거래 가격대가 22.000달러에서 22.145달러 사이였음을 밝히고, 보고인은 요청 시 개별 거래별 상세 정보를 제공하겠다고 명시하고 있습니다.
Kristen M. Oelschlager, directrice des opérations de Castle Biosciences (CSTL), a vendu 12 677 actions ordinaires de la société dans une opération exécutée à un prix moyen pondéré de 22,019 $ par action. La vente déclarée a été réalisée en vertu d'un plan de négociation Rule 10b5-1 adopté par la personne déclarante et, après la transaction, cette personne détenait à titre bénéficiaire 141 116 actions. Le dépôt indique que la vente a eu lieu en plusieurs transactions à des prix compris entre 22,000 $ et 22,145 $ et que la personne déclarante fournira des informations détaillées au niveau de chaque transaction sur demande.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences (CSTL), veräußerte 12.677 Aktien der Stammaktien des Unternehmens in einer Transaktion zu einem gewichteten Durchschnittspreis von 22,019 $ pro Aktie. Der gemeldete Verkauf erfolgte gemäß einem nach Rule 10b5-1 eingerichteten Handelsplan der berichtenden Person und nach der Transaktion hielt die berichtende Person wirtschaftlich 141.116 Aktien. Die Meldung führt aus, dass der Verkauf in mehreren Trades zu Preisen zwischen 22,000 $ und 22,145 $ stattfand und dass die berichtende Person auf Anfrage detaillierte transaktionsbezogene Angaben bereitstellen wird.
- Transaction executed under a Rule 10b5-1 plan, indicating trades were pre-scheduled and aiming to reduce potential timing concerns
- Weighted-average price and price range disclosed, and the reporting person offers to provide detailed trade-level information on request, enhancing transparency
- Reporting person retains a meaningful stake after the sale (141,116 shares), so control was not surrendered
- None.
Insights
TL;DR: Insider executed a planned sale under a 10b5-1 plan; transaction size appears routine relative to disclosed post-sale holdings.
The sale of 12,677 shares at a weighted-average $22.019 was executed under a pre-established Rule 10b5-1 plan, which typically indicates the trades were scheduled in advance to avoid timing concerns. The filing states the trades occurred across a narrow price range and that the reporting person retains 141,116 shares following the disposition. From a market-impact perspective, the disclosure promotes transparency but does not by itself indicate material change to company control or governance.
TL;DR: Use of a 10b5-1 plan and offer to provide trade details signals compliance and governance transparency.
Reporting the disposition and citing a Rule 10b5-1 plan aligns with governance best practices by documenting the affirmative defense for scheduled trades. The filer’s offer to supply trade-level data on request increases disclosure quality. The filing does not report any derivative transactions or other changes in indirect ownership, and it was signed by an attorney-in-fact, consistent with authorized reporting procedures.
Kristen M. Oelschlager, Chief Operating Officer di Castle Biosciences (CSTL), ha venduto 12.677 azioni dell'ordinario della società in un'operazione eseguita a un prezzo medio ponderato di 22,019 $ per azione. La vendita è stata effettuata ai sensi di un piano di negoziazione ai sensi della Rule 10b5-1 adottato dalla persona che ha presentato la segnalazione e, dopo la transazione, la stessa deteneva beneficiariamente 141.116 azioni. La comunicazione specifica che la vendita è avvenuta in più operazioni a prezzi compresi tra 22,000 $ e 22,145 $ e che la persona che ha presentato la segnalazione fornirà informazioni dettagliate a livello di singole operazioni su richiesta.
Kristen M. Oelschlager, directora de operaciones de Castle Biosciences (CSTL), vendió 12.677 acciones del capital social de la compañía en una transacción ejecutada a un precio medio ponderado de 22,019 $ por acción. La venta se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado por la persona informante y, tras la transacción, dicha persona poseía de forma beneficiaria 141.116 acciones. La presentación revela que la venta se efectuó en múltiples operaciones a precios que oscilaron entre 22,000 $ y 22,145 $ y que la persona informante facilitará información detallada por operación si se le solicita.
Castle Biosciences(CSTL)의 최고운영책임자(Chief Operating Officer)인 Kristen M. Oelschlager는 회사 보통주 12,677주를 주당 가중평균 가격 22.019달러에 매도했습니다. 해당 매도는 보고인이 채택한 Rule 10b5-1 거래계획에 따라 이루어졌으며, 거래 후 보고인은 실질적으로 141,116주를 보유하고 있습니다. 제출서류는 매도가 여러 건의 거래로 이루어졌으며 거래 가격대가 22.000달러에서 22.145달러 사이였음을 밝히고, 보고인은 요청 시 개별 거래별 상세 정보를 제공하겠다고 명시하고 있습니다.
Kristen M. Oelschlager, directrice des opérations de Castle Biosciences (CSTL), a vendu 12 677 actions ordinaires de la société dans une opération exécutée à un prix moyen pondéré de 22,019 $ par action. La vente déclarée a été réalisée en vertu d'un plan de négociation Rule 10b5-1 adopté par la personne déclarante et, après la transaction, cette personne détenait à titre bénéficiaire 141 116 actions. Le dépôt indique que la vente a eu lieu en plusieurs transactions à des prix compris entre 22,000 $ et 22,145 $ et que la personne déclarante fournira des informations détaillées au niveau de chaque transaction sur demande.
Kristen M. Oelschlager, Chief Operating Officer von Castle Biosciences (CSTL), veräußerte 12.677 Aktien der Stammaktien des Unternehmens in einer Transaktion zu einem gewichteten Durchschnittspreis von 22,019 $ pro Aktie. Der gemeldete Verkauf erfolgte gemäß einem nach Rule 10b5-1 eingerichteten Handelsplan der berichtenden Person und nach der Transaktion hielt die berichtende Person wirtschaftlich 141.116 Aktien. Die Meldung führt aus, dass der Verkauf in mehreren Trades zu Preisen zwischen 22,000 $ und 22,145 $ stattfand und dass die berichtende Person auf Anfrage detaillierte transaktionsbezogene Angaben bereitstellen wird.
FAQ
What did Castle Biosciences (CSTL) insider Kristen Oelschlager report on Form 4?
Was the insider sale part of a trading plan for CSTL?
How many Castle Biosciences shares does the reporting person own after the sale?
What price range did the CSTL insider trades occur at?
Were any derivative securities or option exercises reported by the insider?
